F0681
Factor V human
aqueous glycerol solution, ≥25 units/mg protein
Sinónimos:
Labile factor, Proaccelerin
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
General description
Factor V is a single chain glycoprotein involved in the blood coagulation cascade. It is the procofactor of Va which accelerates the conversion of prothrombin to thrombin.
Application
Factor V is a key component in blood coagulation systems, where deficiencies can inhibit thrombin generation and affect hemostasis. It has been used in studies of Coagulopathic bleeding which occurs following injury and is a leading cause of in hospital deaths.
Linkage
View this factors role in the Coagulation Cascade.
Unit Definition
One unit is equivalent to the Factor V activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
Physical form
Aqueous solution containing 50% (v/v) glycerol
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Sandro B Rizoli et al.
The Journal of trauma, 71(5 Suppl 1), S427-S434 (2011-12-17)
Coagulopathic bleeding is a leading cause of in-hospital death after injury. A recently proposed transfusion strategy calls for early and aggressive frozen plasma transfusion to bleeding trauma patients, thus addressing trauma-associated coagulopathy (TAC) by transfusing clotting factors (CFs). This strategy
Early coagulopathy in trauma patients: An on-scene and hospital admission study.
Floccard B., et al.
Injury (2010)
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico